当前位置: X-MOL 学术Biomacromolecules › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Recent Advances of Polycationic siRNA Vectors for Cancer Therapy.
Biomacromolecules ( IF 6.2 ) Pub Date : 2020-06-22 , DOI: 10.1021/acs.biomac.0c00438
Raut Bholakant 1 , Hongliang Qian 1 , Junmei Zhang 1 , Xin Huang 1 , Dechun Huang 1 , Jan Feijen 2 , Yinan Zhong 1 , Wei Chen 1
Affiliation  

Small interfering RNAs (siRNAs) have recently emerged as a new class of biopharmaceuticals for the treatment of various diseases, including genetic diseases, viral infections, heritable disorders, and most prominently, cancer. However, clinical applications of siRNA-based therapeutics through intravenous administration have been limited due to their rapid degradation and renal clearance, poor cellular uptake, low cytoplasmic release by escaping endocytic uptake, and off-target effects. The success of siRNA-based therapeutics depends upon the design and creation of efficient delivery vectors that should be able to protect siRNA from in vivo degradation and specifically deliver siRNA to cytosol of target cells. Over the past decade, myriad types of carrier systems composed of cationic polymers have been designed for delivery of siRNA to tumor cells. In this review, we overview recent advances in siRNA delivery by using these promising nonviral carrier systems in diverse approaches to overcome the delivery hindrances and provide valuable understanding to direct the future design of siRNA delivery carriers.

中文翻译:

聚阳离子siRNA载体在癌症治疗中的最新进展。

小干扰RNA(siRNA)最近作为一种新型的生物药物出现,用于治疗各种疾病,包括遗传性疾病,病毒感染,遗传性疾病,最主要的是癌症。但是,基于siRNA的治疗剂通过静脉给药的临床应用受到限制,原因是它们的快速降解和肾脏清除,差的细胞摄取,通过逃逸吞噬内吞作用导致的胞质释放低以及脱靶效应。基于siRNA的治疗方法的成功取决于有效的递送载体的设计和创建,该载体应能够保护siRNA免受体内感染降解并特异性地将siRNA传递到靶细胞的细胞质中。在过去的十年中,已经设计了多种类型的由阳离子聚合物组成的载体系统,用于将siRNA递送至肿瘤细胞。在这篇综述中,我们概述了通过在各种途径中使用这些有前途的非病毒载体系统来克服siRNA递送障碍并提供有价值的理解,以指导siRNA递送载体的未来设计,从而概述了siRNA递送的最新进展。
更新日期:2020-08-10
down
wechat
bug